CD8A and neoplasm: Combining ICB with immune checkpoint inhibitors can partially overcome the adaptive immune resistance in the tumor microenvironment, thus restoring the immune function of CD8+ T lymphocytes in the tumor microenvironment and enhancing the anti-tumor immune response (Pan et al., 2022).